Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
3(27%)
Results Posted
100%(4 trials)
Terminated
1(9%)

Phase Distribution

Ph phase_3
2
18%
Ph phase_2
3
27%
Ph phase_1
6
55%

Phase Distribution

6

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
6(54.5%)
Phase 2Efficacy & side effects
3(27.3%)
Phase 3Large-scale testing
2(18.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

3

trials recruiting

Total Trials

11

all time

Status Distribution
Active(5)
Completed(4)
Terminated(2)

Detailed Status

Completed4
Active, not recruiting3
Not yet recruiting2
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
3
Success Rate
80.0%
Most Advanced
Phase 3

Trials by Phase

Phase 16 (54.5%)
Phase 23 (27.3%)
Phase 32 (18.2%)

Trials by Status

withdrawn19%
completed436%
terminated19%
not_yet_recruiting218%
active_not_recruiting327%

Recent Activity

3 active trials
Showing 5 of 11
withdrawnphase_1

AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer

NCT07146919
not_yet_recruitingphase_2

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

NCT07470840
active_not_recruitingphase_3

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

NCT05052801
completedphase_1

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

NCT05325866
active_not_recruitingphase_3

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.

NCT05111626
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT07146919Phase 1

AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer

Withdrawn
NCT07470840Phase 2

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

Not Yet Recruiting
NCT05052801Phase 3

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Active Not Recruiting
NCT05325866Phase 1

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

Completed
NCT05111626Phase 3

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.

Active Not Recruiting
NCT05322577Phase 1

A Study Evaluating Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer.

Active Not Recruiting
NCT06978062Phase 1

Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment

Not Yet Recruiting
NCT05267470Phase 1

A Study of Bemarituzumab Monotherapy and Combination With Other Anti-cancer Therapy in SqNSCLC With FGFR2b Overexpression (FORTITUDE-201)

Terminated
NCT03694522Phase 2

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer

Completed
NCT03343301Phase 1

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer

Completed
NCT02213289Phase 2

PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11